PKC isozymes in chronic cardiac disease: possible therapeutic targets?
about
MURC, a muscle-restricted coiled-coil protein that modulates the Rho/ROCK pathway, induces cardiac dysfunction and conduction disturbanceDynamics and Membrane Interactions of Protein Kinase CApelin increases cardiac contractility via protein kinase Cε- and extracellular signal-regulated kinase-dependent mechanismsHASF is a stem cell paracrine factor that activates PKC epsilon mediated cytoprotectionC1 Domain-targeted isophthalate derivatives induce cell elongation and cell cycle arrest in HeLa cellsThe C-terminal V5 domain of Protein Kinase Cα is intrinsically disordered, with propensity to associate with a membrane mimeticUp-regulation of endothelin type B receptors in the human internal mammary artery in culture is dependent on protein kinase C and mitogen-activated kinase signaling pathwaysProtein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder.Inhibitory effect of PMC, a potent hydrophilic α-tocopherol derivative, on vascular smooth muscle cell proliferation: the pivotal role of PKC-α translocation.Discovery of small molecule inhibitors of the PH domain leucine-rich repeat protein phosphatase (PHLPP) by chemical and virtual screening.Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.Cardiomyocyte S1P1 receptor-mediated extracellular signal-related kinase signaling and desensitizationExcision of titin's cardiac PEVK spring element abolishes PKCalpha-induced increases in myocardial stiffnessDifferential and conditional activation of PKC-isoforms dictates cardiac adaptation during physiological to pathological hypertrophy.Receptor-independent cardiac protein kinase Calpha activation by calpain-mediated truncation of regulatory domains.Highly Specific Modulators of Protein Kinase C Localization: Applications to Heart FailureGene expression, function and ischemia tolerance in male and female rat hearts after sub-toxic levels of angiotensin II.Protein kinase C isozymes as regulators of sensitivity to and self-administration of drugs of abuse-studies with genetically modified mice.Selective deletion of long but not short Cypher isoforms leads to late-onset dilated cardiomyopathy.Fluorescent-responsive synthetic C1b domains of protein kinase Cδ as reporters of specific high-affinity ligand bindingβIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failurePKCβII inhibition attenuates myocardial infarction induced heart failure and is associated with a reduction of fibrosis and pro-inflammatory responsesReceptor-independent protein kinase C alpha (PKCalpha) signaling by calpain-generated free catalytic domains induces HDAC5 nuclear export and regulates cardiac transcription.PKC δ and βII regulate angiotensin II-mediated fibrosis through p38: a mechanism of RV fibrosis in pulmonary hypertension.Protein kinase Cα as a heart failure therapeutic targetTitin-actin interaction: PEVK-actin-based viscosity in a large animalInhibition of PKCα/β with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury.Studies on the regio- and diastereo-selective epoxidation of daphnanes and tiglianes.Biodistribution and Efficacy of Targeted Pulmonary Delivery of a Protein Kinase C-δ Inhibitory Peptide: Impact on Indirect Lung Injury.Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy.Therapeutic potential for protein kinase C inhibitor in vascular restenosis.Ethanol for cardiac ischemia: the role of protein kinase c.Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin.Protein kinase C and acute respiratory distress syndrome.With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure.Protein kinase C in heart failure: a therapeutic target?Pigment Epithelium-Derived Factor (PEDF) Improves Ischemic Cardiac Functional Reserve Through Decreasing Hypoxic Cardiomyocyte Contractility Through PEDF Receptor (PEDF-R).Rationally designed peptide regulators of protein kinase C.Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approachShort-term Mg deficiency upregulates protein kinase C isoforms in cardiovascular tissues and cells; relation to NF-kB, cytokines, ceramide salvage sphingolipid pathway and PKC-zeta: hypothesis and review.
P2860
Q24309495-0962C2A0-D715-4DC2-A645-91BDEDE6D777Q26799286-951563F2-8227-46C5-8CD4-9BB6510FA96DQ28237326-CF7A701F-2DBC-4F3E-9B33-EC887DB1D303Q28302576-CCAD8D40-811B-49B4-8C47-F7CF21DE1298Q28478227-7B36C560-11C5-4C4C-8045-12667172B4ECQ28533712-EB659DE3-F0D2-4C21-A586-7D291006C6C7Q33367779-F5D35CBD-5E90-4481-A745-D3C69FA67E8EQ33573983-E5AB3188-D3C1-4157-B91C-54E74AD1D664Q33645805-0EB1BE88-DA6D-4377-9A3D-C943BF7C21DAQ33690795-EBA85190-9D0B-4582-9452-8AEA7CD3D583Q33700622-6DB8B921-C03F-4FB1-978F-B140C9AE7A34Q33715382-D63B51D4-2C47-4FD7-95EE-ABB51AAFAA74Q33787977-5498D3F3-6EDF-4D03-BE29-65F1F9072EA9Q34035413-7F383D81-9708-4762-B377-6593BFE3D219Q34168662-960615B2-B52D-40A0-AB6F-4E6EC553EEFAQ34386778-FFE41D7B-9679-4317-BAD4-36E967ED7929Q34561377-5F5CEC23-F66F-46F6-9741-F34EBFDCFC02Q34761380-3D5865FC-B420-4DEB-825B-295A8BACB8F3Q34766977-1533EFBD-9E57-43E4-ADF8-62C91F3F486BQ34792902-6074B870-1BEF-4D7A-85DE-FBB95B2A0462Q35103455-2ECF7D20-51FE-48F3-A8F9-B2B4398741F5Q35106609-D0558CCE-9657-4C97-8F00-C32359754D52Q35128304-B451CFCC-CF43-44E7-A23B-B3B9AA414F8BQ35437493-7998958D-FB96-4546-B3DE-D6A577803AA7Q35480691-CA5C41D3-1871-4079-825F-AD805C835E61Q35582401-17631696-23B4-4548-AA9D-9EBBCF0E01AFQ35612752-59A8F2AE-6DD6-4DB7-8828-FFF278AE861AQ35665829-F22EC934-FE0E-4A2A-97E8-72AC18CE01FAQ36077663-82161586-B2BB-439E-810B-52CB0B4D8731Q36163634-515434E0-A586-462E-8263-5A3F2A2233DEQ36480056-E480D8A1-64A6-49FA-967B-4B8DE26FA0EBQ36694026-FC6B4685-3C10-4E69-A0BC-BB9A0170FF83Q36801721-85E06053-E1DA-4C3A-959D-1B2654BC198AQ37016386-EBA42420-97C7-44C8-9FF4-79D00ED0271CQ37101602-EEA2E21D-B11A-4377-80FA-BFACBF9D8339Q37176180-A990AB21-5E9C-454F-A27F-D322AB0DEC1BQ37240624-5527C7AF-8C83-465B-A7C3-B646B65D02B9Q37271445-32EA1841-A9F9-4462-9644-88DF2A37A1E5Q37359189-9073E08F-06E8-4A6B-92A0-5D54CCB885B0Q37516319-405C42CB-C2D5-4E9E-92DD-5C6FDF8D7AFD
P2860
PKC isozymes in chronic cardiac disease: possible therapeutic targets?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
PKC isozymes in chronic cardiac disease: possible therapeutic targets?
@en
type
label
PKC isozymes in chronic cardiac disease: possible therapeutic targets?
@en
prefLabel
PKC isozymes in chronic cardiac disease: possible therapeutic targets?
@en
P2093
P1476
PKC isozymes in chronic cardiac disease: possible therapeutic targets?
@en
P2093
Alice Vallentin
Eric Churchill
Grant Budas
Tomoyoshi Koyanagi
P304
P356
10.1146/ANNUREV.PHARMTOX.48.121806.154902
P577
2008-01-01T00:00:00Z